STCube

STCube EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of STCube (052020.KQ) as of Oct 24, 2026 is -23.47 B KRW. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -21.51 B KRW — a change of 9.15% (lower).

EBITDA

-23.47 BKRW

YoY

9.15%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of STCube is 2025 -23.47 B KRW. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of STCube was 2024 -21.51 B KRW. It decreases by 9.15% lower compared to the previous year.

The STCube EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
-10.71 B KRW
Jan 1, 2019
-8.54 B KRW
Jan 1, 2020
-11.94 B KRW
Jan 1, 2021
-18.30 B KRW
Jan 1, 2022
-18.15 B KRW
Jan 1, 2023
-25.12 B KRW
Jan 1, 2024
-21.51 B KRW
Jan 1, 2025
-23.47 B KRW
The STCube EBITDA history
YEAREBITDAYoY
-23.47 BKRW+9.15%
-21.51 BKRW-14.40%
-25.12 BKRW+38.42%
-18.15 BKRW-0.83%
-18.30 BKRW+53.33%
-11.94 BKRW+39.80%
-8.54 BKRW-20.30%
-10.71 BKRW-22.27%
-13.78 BKRW+540.70%
-2.15 BKRW-49.30%
-4.24 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

STCube Stock analysis

What does STCube do? STCube Inc. generates revenue through its two business segments. The IT segment distributes CCTV lenses and related components, targeting businesses requiring security solutions. The BT segment develops and licenses immunomodulatory anticancer drug therapeutic candidates, selling to pharmaceutical companies and research institutions. Both segments operate under the company's brand, leveraging its IT and biotechnology expertise. The IT segment focuses on closed-circuit television lens distribution, serving commercial and industrial clients seeking reliable security infrastructure. The BT segment's drug development and licensing activities cater to the pharmaceutical industry, providing innovative therapeutic candidates for cancer treatment. These offerings align with STCube's dual expertise in technology and biotechnology. STCube's revenue streams are derived from product distribution in the IT sector and licensing agreements in the biotechnology sector. The company's clients include businesses needing CCTV components and pharmaceutical firms interested in anticancer drug development. This dual approach allows STCube to serve distinct market segments with specialized solutions. STCube is one of the most popular companies on Eulerpool.

Frequently Asked Questions about STCube stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of STCube is -23.47 B KRW in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of STCube changed from -21.51 B KRW to -23.47 B KRW, representing a 9.15% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) STCube since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s STCube historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — STCube

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — STCube